Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Ionis Pharmaceuticals Inc...

    NASDAQ: IONS · Real-Time Price · USD
    35.28
    -0.31 (-0.87%)
    At close: Jun 16, 2025, 3:59 PM
    36.68
    3.97%
    After-hours: Jun 16, 2025, 07:31 PM EDT
    -0.87%
    Bid 34.69
    Market Cap 5.62B
    Revenue (ttm) 717.44M
    Net Income (ttm) -458.03M
    EPS (ttm) -2.99
    PE Ratio (ttm) -11.8
    Forward PE -11.39
    Analyst Buy
    Ask 37.45
    Volume 880,777
    Avg. Volume (20D) 1,637,030
    Open 35.84
    Previous Close 35.59
    Day's Range 34.77 - 35.85
    52-Week Range 23.95 - 52.34
    Beta 0.18

    About IONS

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol IONS
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for IONS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    7 months ago
    Shares of pharmaceutical and healthcare stocks are... Unlock content with Pro Subscription
    9 months ago
    Ionis Pharmaceuticals shares are trading lower after the company priced its $500.3 million public offering of 11.5 million common shares at $43.50 per share.
    news image

    4 days ago · businesswire.com

    Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026

    CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Richard Geary, Ph.D., executive vice president and chief development officer, will retire effective J...

    news image

    5 days ago · businesswire.com

    First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome

    CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the global Phase 3 REVEAL study, which is designed to evaluat...

    news image

    2 weeks ago · zacks.com

    Why Is Ionis Pharmaceuticals (IONS) Up 5.5% Since Last Earnings Report?

    Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?

    news image

    3 weeks ago · zacks.com

    Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study

    Late-stage data shows that treatment with an 80mg dose of IONS' Tryngolza achieved a 61% placebo-adjusted reduction in triglyceride levels in six months.

    news image

    4 weeks ago · businesswire.com

    Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides

    CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the Essence study of olezarsen in people with moderate hypertriglyceridemia ...

    news image

    1 month ago · businesswire.com

    Ionis to host 2025 virtual Annual Meeting of Stockholders

    CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2025 virtual Annual Meeting of Stockholders followed by a general corpora...

    news image

    1 month ago · zacks.com

    Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View

    IONS reports better-than-expected first-quarter results. The company raises its sales guidance for 2025 by more than 20% on the back of two new licensing deals.

    news image

    1 month ago · seekingalpha.com

    Ionis Pharmaceuticals, Inc. (IONS) Q1 2025 Earnings Call Transcript

    Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q1 2025 Earnings Conference Call April 30, 2025 11:30 AM ET Company Participants Wade Walke - SVP, IR Brett Monia - Founder, CEO & Director Kyle Jenne - EVP ...

    news image

    1 month ago · benzinga.com

    Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge

    Ionis Pharmaceuticals Inc IONS reported a first-quarter EPS loss of 93 cents on Wednesday, down from a loss of 98 cents, beating the consensus of a $1.12 loss.

    news image

    1 month ago · zacks.com

    Ionis Pharmaceuticals (IONS) Reports Q1 Earnings: What Key Metrics Have to Say

    Although the revenue and EPS for Ionis Pharmaceuticals (IONS) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare wit...

    Add to Watchlist